FDA eases some REMS requirements for isotretinoin

FDA approved updates to the iPLEDGE REMS that aim to lessen burdens on patients, prescribers, and pharmacies while maintaining safe-use measures for isotretinoin. Key changes—effective 180 days after the February 9, 2026 approval—allow prescribers to permit pregnancy testing outside a medical setting during and after treatment, though pre‑treatment tests must still be completed in a clinical setting. Patients who can become pregnant may repeat a pregnancy test immediately if they miss the 7‑day pickup window, and those who cannot become pregnant no longer require monthly counseling documentation. Prescribers must establish safeguards to minimize misinterpretation or falsification of patient‑performed tests. Pharmacies will no longer follow the former 30‑day prescription window for patients who cannot become pregnant and must ensure timely authorization reversals if prescriptions are not picked up. Annual pharmacy staff training and recordkeeping are now explicitly required.

Source:

(2026, February 9). Food and Drug Administration. iPLEDGE REMS modification approved to reduce burden while maintaining isotretinoin safe‑use requirements: iPLEDGE Update: FDA approves iPLEDGE REMS modification (February 9, 2026). https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/ipledge-risk-evaluation-and-mitigation-strategy-rems